MITF and melanoma: Indeed, whether some studies, in concordance with our data, have demonstrated that MITF low levels are associated with the acquisition of resistance to targeted therapies in melanoma [29, 36, 38], others have reported that MITF can act as driver of reversible non-mutational drug-tolerance [39, 40].